Functional Genetic Analysis of Klebsiella pneumoniae Hypervirulence

肺炎克雷伯菌高毒力的功能遗传分析

基本信息

项目摘要

Project Summary Klebsiella pneumoniae is one of the most common nosocomial pathogens and is typically associated with urinary tract infections (UTIs), pneumonia, and septicemia. Two lineages of K. pneumoniae have emerged from classical strains that challenge the successful treatment of these infections. One lineage includes hypervirulent strains causing invasive community-acquired infections and the other encompasses carbapenem-resistant (CR) isolates, primarily causing multi-drug resistant UTIs; the transfer of CR to hypervirulent strains is a real and imminent threat as evidenced by the emergence of such strains in Asia. Infections caused by either lineage have greater morbidity and mortality. Hypervirulent strains often exhibit a hypermucoviscous (hmv) phenotype evident when bacterial colonies are pulled off a surface form a long, adherent string. Typically, hmv K. pneumoniae expresses K1 or K2 capsule type and if capsule is ablated the strain becomes non-mucoid and avirulent. The supposition that capsule and hypermucoidy are inextricably linked to hypervirulence is tenuous as UTI isolates are often non-mucoid, encapsulated and infectious; moreover, some reports have identified strains that are encapsulated but avirulent, non-encapsulated but hypermucoid, or hypervirulent but non-mucoid. These observations identify a major gap in our understanding of the molecular mechanisms that control hypermucoviscosity and how it influences K. pneumoniae pathogenesis. Preliminary data suggests that hmv strains phenotypically switch to non-mucoid when grown in human urine, without loss of capsule. We have capitalized on this groundbreaking phenotype to identify genes that, when disrupted, restore hmv in urine or suppress hmv under standard culture conditions. This proposal will use these mutants as a tool to identify capsule-independent mechanisms that control mucoidy and delineate how hmv distinctly influences K. pneumoniae uropathogenesis versus invasive disease. We hypothesize that capsule and mucoidy are linked, but non-synonymous, and that each distinctly influences K. pneumoniae via different infectious routes. Experiments proposed in Aim 1 will investigate the roles of capsule and mucoidy during primary pneumonia and dissemination, identifying capsule-dependent and -independent genes that control mucoidy and their individual contribution to invasive infection. Studies in Aim 2 will evaluate the functional role of mucoidy and capsule during UTI using a model hmv K. pneumoniae strain and two clinical UTI isolates. The successful execution of this proposal will deepen our understanding of the cellular factors that drive mucoidy and capsule, and dissect their contribution to invasive infections versus UTIs. The identification of these cellular factors may provide novel targets for therapeutics and diagnostics, improving our ability to diagnose and treat the most challenging K. pneumoniae infections.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Laura Anzaldi Mike其他文献

Laura Anzaldi Mike的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Laura Anzaldi Mike', 18)}}的其他基金

Control of Klebsiella capsule biosynthesis and attachment
克雷伯菌荚膜生物合成和附着的控制
  • 批准号:
    10713888
  • 财政年份:
    2023
  • 资助金额:
    $ 16.14万
  • 项目类别:
Functional Genetic Analysis of Klebsiella pneumoniae Hypervirulence
肺炎克雷伯菌高毒力的功能遗传分析
  • 批准号:
    10450624
  • 财政年份:
    2021
  • 资助金额:
    $ 16.14万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 16.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 16.14万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 16.14万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 16.14万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 16.14万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 16.14万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 16.14万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 16.14万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 16.14万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 16.14万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了